The subjective effects of 4-Fluoroamphetamine include euphoria which some find similar to the effects of MDMA, increased energy (stimulation), mood elevation, excessive talking, bruxism, and suppressed appetite (anorexic).
4-FA does not cause long-lasting depletion of brain serotonin, unlike its analogues 4-CA and 4-BA. This is thought to "reflect the inability of the fluoro-compound to be metabolized in the same way as the other haloamphetamines."
Contrary to popular belief, neurotoxicity does not increase down the series of para-halogenated amphetamine derivatives, even though serotonin releasing potency does follow this trend. For example, 4-iodoamphetamine is less toxic than is 4-chloroamphetamine. Hence, this property is not related to serotonin releasing potency as such, since PAL-287 was reported to be not at all neurotoxic even though it is a powerful 5-HT releasing agent.
Bearing in mind the above statements, it is unclear where 4-methylamphetamine fits in on the neurotoxicity scale. 4-MTA is an example of a para-substituted, non-neurotoxic amphetamine.
^Rösner, P; Quednow, B; Girreser, U; Junge, T (2005). "Isomeric fluoro-methoxy-phenylalkylamines: a new series of controlled-substance analogues (designer drugs)". Forensic Science International148 (2–3): 143–56. doi:10.1016/j.forsciint.2004.05.003. PMID15639609.
^Nagai, F; Nonaka, R; Satoh Hisashi Kamimura, K (2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". European Journal of Pharmacology559 (2–3): 132–7. doi:10.1016/j.ejphar.2006.11.075. PMID17223101.
^Fuller, R. W.; Baker, J. C.; Perry, K. W.; Molloy, B. B. (1975). "Comparison of 4-chloro-, 4-bromo- and 4-fluoroamphetamine in rats: Drug levels in brain and effects on brain serotonin metabolism". Neuropharmacology14 (10): 739–746. doi:10.1016/0028-3908(75)90099-4. PMID1196472.edit
^Rothman, R. B.; Blough, BE; Woolverton, WL; Anderson, KG; Negus, SS; Mello, NK; Roth, BL; Baumann, MH (2005). "Development of a Rationally Designed, Low Abuse Potential, Biogenic Amine Releaser That Suppresses Cocaine Self-Administration". Journal of Pharmacology and Experimental Therapeutics313 (3): 1361–1369. doi:10.1124/jpet.104.082503. PMID15761112.edit
^Huang, X.; Marona-Lewicka, D.; Nichols, D. E. (1992). "P-methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent". European journal of pharmacology229 (1): 31–38. doi:10.1016/0014-2999(92)90282-9. PMID1473561.edit
^Li, Q; Murakami, I; Stall, S; Levy, AD; Brownfield, MS; Nichols, DE; Van De Kar, LD (1996). "Neuroendocrine pharmacology of three serotonin releasers: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (MBDB), 5-methoxy-6-methyl-2-aminoindan (MMAi) and p-methylthioamphetamine (MTA).". The Journal of Pharmacology and Experimental Therapeutics279 (3): 1261–7. PMID8968349.
^Murphy, J; Flynn, JJ; Cannon, DM; Guiry, PJ; McCormack, P; Baird, AW; McBean, GJ; Keenan, AK (2002). "In vitro neuronal and vascular responses to 5-hydroxytryptamine: modulation by 4-methylthioamphetamine, 4-methylthiomethamphetamine and 3,4-methylenedioxymethamphetamine.". European Journal of Pharmacology444 (1–2): 61–7. doi:10.1016/S0014-2999(02)01586-8. PMID12191583.
^Fisher MB, Henne KR, Boer J (2006). "The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism". Current Opinion in Drug Discovery & Development9 (1): 101–9. PMID16445122.
^E. Costa and S. Garattini (1970) Amphetamines and Related Compounds, p.28, New York: Raven Press.